-
Je něco špatně v tomto záznamu ?
Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy
J. Slama, P. Dundr, L. Dusek, D. Fischerova, I. Pinkavova, M. Zikan, P. Vrzackova, M. Kojanova, D. Cibula
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- adjuvantní chemoterapie MeSH
- biopsie sentinelové lymfatické uzliny metody MeSH
- dospělí MeSH
- hysterektomie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfadenektomie MeSH
- lymfatické metastázy MeSH
- lymfatické uzliny patologie MeSH
- mladý dospělý MeSH
- nádory děložního čípku farmakoterapie patologie chirurgie MeSH
- neoadjuvantní terapie MeSH
- retrospektivní studie MeSH
- rosanilinová barviva diagnostické užití MeSH
- senioři MeSH
- staging nádorů MeSH
- technecium diagnostické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: Neoadjuvant chemotherapy (NAC) is used in locally advanced cervical cancers with the aim to decrease the size of the tumor and to allow for less radical surgery. Despite of the fact that the high response rate of the tumor has been well established, the impact of NAC on sentinel lymph node (SN) detection and status has not been explored to date. METHODS: Our study included 82 patients with locally advanced cervical cancers (FIGO IB1 >3 cm, IB2, IIA2 and selected IIB) out of which 51 patients were referred to SN biopsy prior to NAC and 31 patients to radical surgical procedure including SN biopsy after three courses of "dose density" NAC. In both groups, the prevalence of macrometastases, micrometastases and isolated tumor cells (ITC) in SN was compared. RESULTS: The total of 179 SNs was evaluated. SN detection rate in the whole cohort reached 87.8% per patient and 60.9% bilaterally, without significant difference between both groups. In the group with upfront SN biopsy prior to NAC the prevalence of macrometastases, micrometastases and ITC amounted to 43.1% (22/51), 7.8% (4/51) and 7.8% (4/51) respectively. In the group with SN biopsy after previous NAC, macrometastases were detected in 22.6 (7/31) of patients in SN, whereas there was only one micrometastasis and no ITC detected in that group. CONCLUSIONS: Neoadjuvant chemotherapy did not influence the detection rate of SNs, yet it was associated with significantly reduced prevalence of metastatic involvement of SNs, especially almost completely eliminating low volume disease.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12024018
- 003
- CZ-PrNML
- 005
- 20170411101031.0
- 007
- ta
- 008
- 120815s2012 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ygyno.2012.02.010 $2 doi
- 035 __
- $a (PubMed)22342976
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sláma, Jiří $7 xx0105772 $u Gynecologic Oncology Center, General Faculty Hospital and 1st School of Medicine, Charles University, Prague, Czech Republic. jiri.slama@vfn.cz
- 245 10
- $a Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy / $c J. Slama, P. Dundr, L. Dusek, D. Fischerova, I. Pinkavova, M. Zikan, P. Vrzackova, M. Kojanova, D. Cibula
- 520 9_
- $a OBJECTIVES: Neoadjuvant chemotherapy (NAC) is used in locally advanced cervical cancers with the aim to decrease the size of the tumor and to allow for less radical surgery. Despite of the fact that the high response rate of the tumor has been well established, the impact of NAC on sentinel lymph node (SN) detection and status has not been explored to date. METHODS: Our study included 82 patients with locally advanced cervical cancers (FIGO IB1 >3 cm, IB2, IIA2 and selected IIB) out of which 51 patients were referred to SN biopsy prior to NAC and 31 patients to radical surgical procedure including SN biopsy after three courses of "dose density" NAC. In both groups, the prevalence of macrometastases, micrometastases and isolated tumor cells (ITC) in SN was compared. RESULTS: The total of 179 SNs was evaluated. SN detection rate in the whole cohort reached 87.8% per patient and 60.9% bilaterally, without significant difference between both groups. In the group with upfront SN biopsy prior to NAC the prevalence of macrometastases, micrometastases and ITC amounted to 43.1% (22/51), 7.8% (4/51) and 7.8% (4/51) respectively. In the group with SN biopsy after previous NAC, macrometastases were detected in 22.6 (7/31) of patients in SN, whereas there was only one micrometastasis and no ITC detected in that group. CONCLUSIONS: Neoadjuvant chemotherapy did not influence the detection rate of SNs, yet it was associated with significantly reduced prevalence of metastatic involvement of SNs, especially almost completely eliminating low volume disease.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hysterektomie $7 D007044
- 650 _2
- $a lymfadenektomie $7 D008197
- 650 _2
- $a lymfatické uzliny $x patologie $x radioizotopová diagnostika $7 D008198
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rosanilinová barviva $x diagnostické užití $7 D012394
- 650 _2
- $a biopsie sentinelové lymfatické uzliny $x metody $7 D021701
- 650 _2
- $a technecium $x diagnostické užití $7 D013667
- 650 _2
- $a nádory děložního čípku $x farmakoterapie $x patologie $x chirurgie $7 D002583
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dundr, Pavel $7 xx0080436
- 700 1_
- $a Dusek, L
- 700 1_
- $a Fischerova, D
- 700 1_
- $a Pinkavová, Ivana, $d 1976- $7 xx0103207
- 700 1_
- $a Zikán, Michal, $d 1976- $7 xx0096708
- 700 1_
- $a Vrzackova, P
- 700 1_
- $a Kojanova, M
- 700 1_
- $a Cibula, David, $d 1968- $7 jo20000074072
- 773 0_
- $w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 125, č. 2 (2012), s. 303-306
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22342976 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120815 $b ABA008
- 991 __
- $a 20170411101330 $b ABA008
- 999 __
- $a ok $b bmc $g 946166 $s 781346
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 125 $c 2 $d 303-306 $e 20120214 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
- LZP __
- $a Pubmed-20120815/12/02